Sign In
Buy PFE
$25.69
+0.335 (+1.32%)
At Close: Jun 04, 2026
Compared to Estimates, Pfizer (PFE) Q1 Earnings: A Look at Key Metrics
11:01am, Tuesday, 29'th Apr 2025
While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to
Pfizer delivers mixed results for Q1, expands cost-cutting program
10:45am, Tuesday, 29'th Apr 2025
Pfizer Inc (NYSE:PFE, ETR:PFE) reported mixed results for the first quarter, including an earnings beat but revenue below expectations. Revenue fell 8% from the year-ago quarter to $13.7 billion, belo
Pfizer (PFE) Surpasses Q1 Earnings Estimates
08:55am, Tuesday, 29'th Apr 2025
Pfizer (PFE) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.82 per share a year ago.
Got $5,000: These Dividend Stocks Trade at a 52 Week Low
08:38am, Tuesday, 29'th Apr 2025
Are you ahead, or behind on retirement? SmartAsset's free tool can match you with a financial advisor in minutes to help you answer that today.
Pfizer's plunging Paxlovid sales impact revenue as COVID fades
08:14am, Tuesday, 29'th Apr 2025
Pfizer Inc.'s stock moved lower in premarket trading on Tuesday after the drugmaker fell short of Wall Street's revenue estimate, as sales of its COVID-19 medicine Paxlovid plunged by 75% on fading de
BMO's Evan Seigerman breaks down Pfizer and Regeneron's Q1 results
08:11am, Tuesday, 29'th Apr 2025
Evan David Seigerman, BMO head of healthcare research, joins 'Squawk Box' to break down Pfizer and Regeneron's quarter earnings results.
If You'd Invested $10,000 in Pfizer Stock 10 Years Ago, Here's How Much You'd Have Today
07:45am, Tuesday, 29'th Apr 2025
Few would dispute that Pfizer (PFE 0.63%) is an icon within the pharmaceutical world. And, giving credit where it's due, the drugmaker largely led the charge against the COVID-19 pandemic with both a
Pfizer Revenue Slides as Paxlovid Sales Fade
07:22am, Tuesday, 29'th Apr 2025
Pfizer recorded lower first-quarter revenue on a 75% drop in sales of its Covid-19 treatment, which more than offset growth in other drugs and product categories.
Pfizer expands cost cuts, tops quarterly profit estimates even as sales fall
06:59am, Tuesday, 29'th Apr 2025
Pfizer expanded its cost-cutting efforts and reported first-quarter profit that topped estimates, even as the company's sales fell, largely due to dwindling Covid revenue. The cuts aim to help the pha
Pfizer misses quarterly sales estimates as COVID treatment revenue falls
06:54am, Tuesday, 29'th Apr 2025
U.S. drugmaker Pfizer reported first-quarter revenue below Wall Street estimates on Tuesday, hurt by a decline in sales of its COVID antiviral treatment, Paxlovid.
Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance
06:45am, Tuesday, 29'th Apr 2025
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2025 and reaffirmed its 2025 financial guidance(1). EXECUTIVE COMMENTARY Dr. Albert Bourla, Chair
Pfizer Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
02:45am, Tuesday, 29'th Apr 2025
Pfizer Inc. PFE will release earnings results for the first quarter, before the opening bell on Tuesday, April 29.
Will These 5 Big Drug Stocks Surpass Q1 Earnings Forecasts?
01:11pm, Monday, 28'th Apr 2025
Let's look at five pharma and drug companies, PFE, LLY, AMGN, BIIB and REGN, which are scheduled to release their first-quarter 2025 results later this week.
4 Top Value Stocks to Invest in as US-Global Trade Talks Unfold
09:20am, Monday, 28'th Apr 2025
Value investing is essentially about selecting cheap but fundamentally sound stocks. STNE, CSV, ASB & PFE boast low P/CF ratios.
3 Dividend Stocks to Buy and Hold for the Next Decade
07:47am, Monday, 28'th Apr 2025
Many income investors would love to have a low-maintenance portfolio that doesn't require constant attention. They'd prefer to buy great stocks and rake in the dividends without any hiccups.
